Hope Care, a European digital health company specialising in regulated remote patient monitoring technology, has closed a €6 million Series A funding round consisting entirely of new capital. The round was led by Iberis Capital, with participation from Vieira de Matos – VDM Capital, S.A. and existing shareholder Buenavista Equity Partners.

The funding will support Hope Care’s continued expansion across Europe, strengthen its commercial and operational capabilities, and accelerate the deployment of remote patient monitoring programmes in key healthcare markets.

The company currently delivers remote patient monitoring programmes in Portugal and France, including within GHT Saône-et-Loire Bresse Morvan, while a project is underway in Switzerland.

In Germany, Hope Care has recently established Hope Care GmbH, headquartered at Medical Valley in Erlangen, one of Europe’s leading healthcare innovation hubs. The company’s first German deployment is scheduled to launch in October 2026.

In Romania, Hope Care is advancing a new project and establishing a local presence, with setup activities scheduled to begin by the end of September 2026.

This international growth builds on Hope Care’s established scale in Portugal, where its technology is used by 15 Local Health Units covering approximately 45% of all registered SNS users, as well as the Regional Health Services of Madeira and the Azores. Beyond the public health system, the platform is also deployed across private healthcare providers, social care organisations and municipalities.

Hope Care continued its growth in 2026, with first-half sales reaching 2.5 times the level recorded in the first half of 2025.

Hope Care develops OpMA®, a regulated platform that powers centralised remote care and telehealth centres. By bringing together medical-device data, patient-reported outcomes and clinical workflows in a single environment, the platform enables healthcare organisations to design, deploy and scale digital care programmes across multiple chronic conditions, supporting proactive intervention and more efficient care delivery.

Hope Care’s programmes have demonstrated measurable clinical and economic impact. In a 12-month analysis of 43 people living with chronic obstructive pulmonary disease, one programme was associated with a 76% reduction in hospital days and a 74% reduction in emergency department visits, resulting in estimated annual savings of €4,811 per patient.

“This Series A marks a new stage for Hope Care,” said José Paulo Carvalho, Founder and CEO of Hope Care. “After more than a decade working with healthcare institutions, we have built a regulated platform that delivers measurable outcomes for patients, healthcare professionals and healthcare systems. With the support of our investors, we are now well positioned to accelerate our European expansion and bring this model of care to more healthcare organisations.”

“Across Europe, health systems are straining under the weight of chronic disease, still responding to crises rather than preventing them,” said João Henriques, Partner at Iberis Capital. “Hope Care is one of the few companies that pairs proven clinical evidence with the regulatory maturity to operate inside public health systems at scale. This is a model we are proud to help scale across Europe, since it helps clinicians improve outcomes for patients and ultimately the sustainability of care.”

OpMA® is the commercial name of HCAlert V1.3, certified as a Class IIb Software as a Medical Device (SaMD) under Regulation (EU) 2017/745 (MDR).